InvestorsHub Logo
Followers 594
Posts 20577
Boards Moderated 0
Alias Born 02/01/2012

Re: twiz0019 post# 26574

Saturday, 11/29/2014 7:28:16 PM

Saturday, November 29, 2014 7:28:16 PM

Post# of 48316
Yervoy had more patients treated than Keytruda over the past 3 years so that the FDA is more comfortable with it as the Primary therapy. However a Ketruda/EP-IL-12 Combo as a BLA Commercial could easily surpass the FDA patients number critera and become a Primary option and therefore at least on a par with Yervoy.